Ningbo Meishan Baoshui Gangqu Weijing Rongxi Touzi Guanli Youxian Gongsi

What Ningbo Meishan Baoshui Gangqu Weijing Rongxi Touzi Guanli Youxian Gongsi does

Vigintillion Capital (legal entity: Ningbo Meishan Baoshui Gangqu Weijing Rongxi Touzi Guanli Youxian Gongsi / 惟精资本) is a China-based private equity and venture capital firm founded in 2016 and registered with the Asset Management Association of China (AMAC) under registration number P1061033. The firm is operationally headquartered in Beijing (Room 508, Guohang Building, 36 Xiaoyun Road, Chaoyang District), with a registered entity in the Ningbo Meishan bonded-port area. Its investment platform is specialised in life sciences and healthcare, deploying capital into growth and maturity-stage companies both in China and abroad, with stated portfolio coverage spanning biotech, small molecule FIC/BIC drugs, CDMO services, structural cardiovascular devices, healthcare SaaS, and formulations.

The firm's "product" is a professional PE/VC investment management platform coupled with what it describes as hundreds of industry-academia-research ecosystems covering approximately 20 medical and health sub-sectors, enabling "active analysis and independent exploration" and the transmission of tailor-made strategic value to portfolio companies. Core institutional supporters include China Resources Phoenix Healthcare Group (Asia's largest hospital operator, 107 hospitals, 11,780 beds), China Cinda Asset Management (state-owned MOF-controlled, HK-listed) and Yuexiu Group, alongside an academic partnership with China Pharmaceutical University.

The revenue model is conventional PE: management fees and carried interest on funds raised from limited partners — primarily the supporting conglomerates above plus other institutional investors. No AUM, fund vintage, fee schedule, or revenue figure is publicly disclosed in the available data, and no portfolio company logos, deal-by-deal track record, or aggregate invested capital have been reported. The firm is led by Chairman and Founding Partner Kevin Guan (formerly Executive Director and Healthcare Investment Head at Pacific Alliance Group with stated $30B AUM; Wharton MBA, Tsinghua PBC EMBA, CFA, CPA) and Managing Director Brook Wu (nearly 30 years across Pfizer, MSD, Abbott, Takeda, Mundipharma and China Resources Double-Crane; USC Marshall MBA, China Pharmaceutical University pharmacy degree, founder of China Pharmaceutical BD Alliance).

Name

Ningbo Meishan Baoshui Gangqu Weijing Rongxi Touzi Guanli Youxian Gongsi

Legal name

Ningbo Meishan Baoshui Gangqu Weijing Rongxi Touzi Guanli Youxian Gongsi

Website

https://vigintillion.cn

Company type

Private

Founded year

2016

Operating status

Operating

Short description

Vigintillion Capital (惟精资本) is a China-based, AMAC-registered private equity firm founded in 2016 that invests in growth and maturity-stage life sciences and healthcare companies in China and abroad, including biotech, CDMO, devices and healthcare SaaS.

Ownership category

akta.pro rank

Product category

Healthcare Private Equity Investment

NAICS

Portfolio Management and Investment Advice (523940), All Other Financial Investment Activities (52399)

SIC

Investment Advice (6282)

akta.pro industry

PRIMARYFSANAAAD

Sector-Focused Venture Capital (Vertical Specialists)

Financial & Insurance/Private Equity & Venture Capital/Venture Capital Firms

SECONDARYFSANAAAC

Late-Stage Venture Capital (Series C+)

Financial & Insurance/Private Equity & Venture Capital/Venture Capital Firms

Keywords

• Private equity investment
• Healthcare investment
• Life sciences investing
• Venture capital management
• Biotech growth capital

Headquarters

HQ city

Ningbo

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Distribution channels1 record

Marketing channels1 record

Core offering

Vigintillion Capital is a private equity firm approved by the Asset Management Association of China (AMAC, Registration No. P1061033) that manages investment funds focused exclusively on life sciences and healthcare. The firm invests in growth and maturity stage companies in China and abroad across biotech, small molecule FIC/BIC drugs, CDMO services, structural cardiovascular devices, and healthcare SaaS, while delivering tailor-made strategic value to portfolio companies to support their long-term development.

Product overview

Vigintillion Capital (惟精资本) operates as a single unified private equity investment platform focused on life sciences and healthcare. The firm provides investment management services targeting growth and maturity stage companies in China and abroad. Their portfolio spans multiple healthcare sub-sectors including biotech, small molecule FIC/BIC drugs, CDMO services, structural cardiovascular devices, and healthcare SaaS. As a specialized asset management platform registered with AMAC, they offer institutional investors access to their investment products through direct fund participation.

Differentiator

Problem solved

Functional benefit

Products and services

• Vigintillion Capital Private Equity Investment Platform A professional private equity investment platform approved by AMAC (Registration No. P1061033), specializing in investment management for life sciences and healthcare growth and maturity stage companies in China and abroad, with portfolio coverage across biotech, small molecule FIC/BIC, CDMO services, structural cardiovascular devices, and healthcare SaaS.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core and minor.

• China Resources Phoenix Healthcare Group (华润凤凰医疗集团)coreStrategic or Co-development PartnerIn April 2016, under China Resources Medical's leadership, China Resources Phoenix Healthcare invested in Vigintillion Capital and both parties signed a Comprehensive Strategic Cooperation Agreement. The reorganized China Resources Phoenix Healthcare operates 107 hospitals with 11,780 beds in mainland China, making it the largest medical service group in Asia.
• China Pharmaceutical University (中国药科大学)minorStrategic or Co-development PartnerFirst national pharmacy college founded in 1936, a '211 Project' key university and 'Double First-Class' university. The School of Basic Medical Sciences and Clinical Pharmacy focuses on pathogenesis of major diseases, drug efficacy mechanisms, and rational clinical medicine use. Serves as academic partnership for industry-academia-research ecosystem.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Lake Bleu Capital: Healthcare-focused investment firm covering therapeutics, medical devices, diagnostics, and digital health across China and Asia. Comparable as a sector-specialist growth investor in life sciences.
• 3E Bioventures Capital: Specialist healthcare venture capital and growth firm investing across therapeutics, medical devices, and digital health. Directly comparable as a sector-specialist China-based life sciences investor targeting growth-stage opportunities.
• LYFE Capital: Healthcare-focused growth equity firm investing in pharma, medtech, and diagnostics companies in China and globally. Highly comparable given its similar vertical specialization, growth-stage focus, and cross-border healthcare mandate.
• Highlight Capital: Healthcare-specialized private equity firm investing in growth-stage pharmaceutical, medical device, and life sciences companies in China. Comparable in vertical focus, deal size, and target company stage to Vigintillion.
• Qiming Venture Partners: One of China's most active healthcare-focused venture capital and growth equity firms, investing across biotech, medical devices, diagnostics, and healthcare services. Directly comparable as a China-based, sector-specialized life sciences investor serving growth and maturity-stage companies.
• Loyal Valley Capital: China-based private equity firm with deep healthcare and biotech specialization across growth and mature stages. Directly comparable as a sector-focused PE investor in Chinese life sciences with cross-border exposure.

Broad incumbents

• CDH Investments: Large China-focused private equity firm with healthcare exposure through growth and buyout deals across pharma, devices, and services. Comparable on healthcare PE but as a broad incumbent across multiple sectors.
• HongShan (formerly Sequoia Capital China): One of China's largest venture and growth equity firms with active healthcare and biotech practice. Comparable as a growth-stage investor in Chinese life sciences but operates as a broad incumbent across technology and consumer sectors.
• Hillhouse Capital: Major Asia-focused investment firm with a substantial healthcare and life sciences practice across venture, growth, and public equities. Overlaps with Vigintillion on healthcare PE but operates at much broader scale and mandate across multiple sectors.
• OrbiMed: Global healthcare-dedicated investment firm with significant Asia-Pacific presence across all stages of pharma, medtech, and diagnostics. Overlaps with Vigintillion's healthcare focus but at much larger scale and with global LP base.

Market position

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ningbo Meishan Baoshui Gangqu Weijing Rongxi Touzi Guanli Youxian Gongsi